0001399529-20-000090.txt : 20201106
0001399529-20-000090.hdr.sgml : 20201106
20201106175844
ACCESSION NUMBER: 0001399529-20-000090
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201104
FILED AS OF DATE: 20201106
DATE AS OF CHANGE: 20201106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paglia Regina M.
CENTRAL INDEX KEY: 0001813985
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36281
FILM NUMBER: 201295507
MAIL ADDRESS:
STREET 1: C/O DICERNA PHARMACEUTICALS, INC.
STREET 2: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc
CENTRAL INDEX KEY: 0001399529
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205993609
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617 621 8097
MAIL ADDRESS:
STREET 1: 33 HAYDEN AVENUE
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
wf-form4_160470350893109.xml
FORM 4
X0306
4
2020-11-04
0
0001399529
Dicerna Pharmaceuticals Inc
DRNA
0001813985
Paglia Regina M.
C/O DICERNA PHARMACEUTICALS, INC.
33 HAYDEN AVENUE
LEXINGTON
MA
02421
0
1
0
0
Chief Human Resources Officer
Common Stock
2020-11-04
4
M
0
30000
12.93
A
30000
D
Common Stock
2020-11-04
4
S
0
15000
22.25
D
15000
D
Common Stock
2020-11-04
4
S
0
15000
23.25
D
0
D
Employee Stock Option (Right to Buy)
12.93
2020-11-04
4
M
0
30000
0
D
2029-02-28
Common Stock
30000.0
150000
D
The Reporting Person sold an aggregate of 30,000 shares of common stock on November 4, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 11.43% of 262,450 shares of common stock, which is the number of shares of common stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2020.
The option vested 25% on the first year anniversary of the vesting start date of February 19, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued service with the Issuer through each applicable vesting date.
/s/ Douglas W. Pagan, attorney-in-fact
2020-11-06